PURPOSE Cisplatin-based combination chemotherapy remains the standard of care for
locally advanced or metastatic urothelial cancer (la/mUC); however, toxicity is substantial …

Management of first-line advanced urothelial carcinoma (UC) has consisted during the past
three decades in the administration of platinum-based chemotherapy followed by …

Urothelial carcinoma (UC) is a common cancer associated with a poor prognosis in patients
with advanced disease. Platinum-based chemotherapy has remained the cornerstone of …

Background Pembrolizumab plus lenvatinib has shown antitumor activity and acceptable
safety in patients with platinum-refractory urothelial carcinoma (UC). Objective To evaluate …

Background/Aim: This study retrospectively investigated the impact of enfortumab vedotin
(EV) monotherapy on the oncological outcome, safety profile, and health-related quality of …

Importance The treatment paradigm for advanced urothelial carcinoma (aUC) has
undergone substantial transformation due to the introduction of effective, novel therapeutic …

Introduction Patients with locally advanced/metastatic urothelial carcinoma (la/mUC) have a
poor prognosis. With recent therapeutic advances, data on real-world treatment patterns and …

Context Platinum-based combination chemotherapy is the standard treatment for advanced
or metastatic urothelial carcinoma (AMUC). However, data comparing the efficacy of different …

Introduction Despite rapid advances in the treatment landscape of urothelial cancer, there is
a substantial unmet need for safe and effective therapies for patients with locally advanced …

Urothelial carcinoma is a common malignancy that affects the urinary system, with bladder
cancer being the most prevalent form. Although the management of early-stage disease has …